Acrivastine
A short-acting antihistamine that relieves allergy symptoms such as sneezing, runny nose, and itchy eyes by blocking histamine receptors involved in allergic reactions. It is less sedating than older antihistamines and is often combined with a decongestant to treat nasal congestion alongside allergy symptoms. It requires dosing three times daily due to its relatively brief duration of action.
Masse moléculaire
348,4000 g/mol
LogP
1,60
TPSA
53,40 Ų
Règle des 5 de Lipinski
Conforme
Mécanisme d'action
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Structure 2D
Cite this structure
Embed this structure
SMILES
Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1
InChI
InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
Molecular Formula
C22H24N2O2
HBD / HBA
1 / 4
Liaisons Rotatives
6
Atomes Lourds
26
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A short-acting antihistamine that relieves allergy symptoms such as sneezing, runny nose, and itchy eyes by blocking histamine receptors involved in allergic reactions. It is less sedating than older antihistamines and is often combined with a decongestant to treat nasal congestion alongside allergy symptoms. It requires dosing three times daily due to its relatively brief duration of action.
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Yes, Acrivastine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1224. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5284514. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="acrivastine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/acrivastine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/acrivastine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/acrivastine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="acrivastine"></drugfyi-drug>